TRIDENT is built to be used. Every molecular layer is measured on the same biopsies and tied to the same clinical outcomes, and the consortium welcomes proposals from academic and industry investigators.
Enough to judge whether TRIDENT holds the material a proposed study needs. Individual-level data are released only through the consortium process below.
Centrally scored histology and whole-slide images, electron micrographs, bulk RNA sequencing of microdissected glomeruli and tubules, single-nucleus RNA sequencing, whole-exome sequencing, Xenium 5k spatial transcriptomics, plasma and urine proteomics, urine single-cell RNA sequencing, and coded clinical data with longitudinal eGFR and outcomes. Metabolomics and DNA methylation are in production.
Data are available through the consortium under its data-access policy. Send a short description of the question, the data layers needed and the analysis plan to the study leadership; proposals are reviewed by the consortium and, when approved, data are released in coded form under a data use agreement.
Investigators may propose ancillary studies using banked plasma, urine and tissue or the existing data. Proposals are reviewed for scientific merit, overlap with ongoing work and sample availability.
Manuscripts and abstracts using TRIDENT data are circulated to the consortium before submission and acknowledge TRIDENT and its funders. The publications page lists the consortium's papers with DOIs.
The population-scale spatial atlas was built with TRIDENT biopsies at its core. Partners can place their own sections and single-cell data on it; write to the study leadership to propose a pilot.
Consortium members enter data and documents through the TRIDENT REDCap instance.
